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Background
Riociguat, an oral soluble guanylate cyclase (sGC) sti-
mulator, is currently being investigated for the treat-
ment of pulmonary hypertension. Riociguat has a novel
dual mode of action, directly stimulating sGC, indepen-
dent of nitric oxide (NO), and increasing sensitivity of
sGC to NO. Riociguat thereby restores the NO–sGC–
cGMP pathway, which is impaired in pulmonary hyper-
tension. Three pharmacokinetic studies were per-
formed to characterize the absorption behavior of
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Figure 1 Plasma riociguat concentrations following single 1 mg intravenous (n=22) or oral doses of riociguat (n=22) (absolute bioavailability study).
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Methods
The pharmacokinetic and safety profiles of riociguat were
investigated in three open-label, randomized, crossover
studies in healthy male subjects. In the absolute bioavail-
ability study, fasted subjects (n = 22) received a single
oral immediate-release dose of riociguat 1 mg or intrave-
nous riociguat 1 mg. In the food-effects study, subjects (n
= 23) received a single oral dose of immediate-release
riociguat 2.5 mg after a 10-hour fast or after a high-fat
high-calorie breakfast eaten within 30 minutes of dosing.
In the dose-proportionality study, fasted subjects (n = 24)
received a single oral dose of riociguat 0.5, 1, 1.5, 2, or
2.5 mg.
Results
In the absolute bioavailability study, riociguat exposure
was similar after oral and intravenous dosing and oral
bioavailability was 94% (95% confidence interval: 83–107)
(Figure 1). Mean Cmax of riociguat was slightly lower
after oral dosing compared with intravenous dosing. In
the food-effects study, a high-fat breakfast had little effect
on the extent of riociguat absorption, although absorp-
tion was delayed (Table 1). In fed subjects, the Cmax of
riociguat decreased by 35.3% and tmax increased com-
pared with fasted subjects. In the dose-proportionality
study, systemic exposure of riociguat was dose-propor-
tional over 0.5–2.5 mg (Figure 2) with low intra-indivi-
dual variability and moderate-to-high inter-individual
variability. Riociguat was well tolerated in all studies. The
most common treatment-emergent and riociguat-related
adverse events were headache, flushing, and nasal con-
gestion across all studies.
Conclusion
Riociguat shows complete oral absorption with no clini-
cally relevant food effects; riociguat can therefore be
Table 1 Riociguat pharmacokinetics following a single oral dose of riociguat 2.5 mg in fed and fasted subjects
(food-effects study)
Parametera Fasted (n=23) Fed (n=23) Estimated fed:fasted ratio (%) 90% CI %CV
Cmax (μg/L) 84.2 (44.7−152.7) 54.8 (28.9−91.4) 64.7 57.8–72.5 22.5
tmax (h) 1 (0.5−4.0) 4 (1.5−6.0) — — —
AUC0-∞ (μg⋅h/L) 572.2 (112.3−1300.0) 505.6 (113.3−1205.0) 88.3 82.2–95.0 14.3
AUC, area under the plasma concentration–time curve; CI, confidence interval; Cmax, maximum riociguat plasma concentration; CV, coefficient of variation; tmax,
time to reach Cmax.
aData are mean (range) except tmax, which is median (range).
Figure 2 Mean plasma riociguat concentrations following single oral doses of riociguat 0.5, 1.0, 1.5, 2.0, or 2.5 mg (n=24) (dose-proportionality
study). LLOQ, lower limit of quantification.
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taken with or without food. Riociguat systemic exposure
increased dose proportionally over all doses (0.5–2.5 mg),
supporting the suitability of the individualized dose-
titration scheme used in the Phase III pulmonary arterial
hypertension (PATENT) and chronic thromboembolic
pulmonary hypertension (CHEST) studies.
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